Abstract
Therapy based on the adoptive transfer of T cells expressing chimeric antigen receptors (CAR) have been showing good results in safety and efficacy against B cell malignancies. However, efficacy is still limited in solid tumors, mainly due to mechanisms of immunosuppression, hypoxia , nutrient deprivation and low infiltration of immune cells in the tumor microenvironment. Therefore, a com…